The successful outcomes of research in Immuno-oncology (IO) have led to immunotherapy becoming an essential component of cancer treatment today. This is underlined by the substantial investment in immuno-oncology drug development, with a 91% increase over the last 2 years resulting in 3,876 drugs currently in development. These are to 468 different active targets, which itself is a 78% increase in just 2 years, demonstrating the sustained increase in research and clinical development by industry in this exciting, evolving field. In the last two years, this interest and investment into drug development and clinical research has resulted in 31 FDA approvals for IO therapies. It is estimated that the IO drug market will grow from $14B in 2019 to $34B in 2024. Research continues at pace globally, with the National Cancer Institute (NCI) allocating $6B of funding per year from 2018-2022.
Nat Rev Drug Discov 18, 899-900 (2019) and Nat Rev Drug Discov 17, 783–784 (2018)
3876
Drugs currently in development
468
Different IO active targets
31
FDA approvals for IO therapies
(2018 to 2020)
As the field has accelerated, the issue of tumor resistance has arisen and is now a key area of high unmet medical need for cancer researchers to understand and address.
Through our interactions with the global immuno-oncology community, we have created a series of interactive digital sessions dedicated to highlighting the latest breakthroughs in cell therapies, resistance to immunotherapies (tumor microenvironment and overcoming acquired resistance), and multiplex technologies.
In creating this unique month of interactive activities, it is our hope to enable the whole community to gain insights into approaches impacting the field through talks by thought leaders from across both industry and academia, live discussions and Q&A sessions.
EXPERT INSIGHT
Leeat Keren, Principal Investigator at the Weizmann Institute of Science shares her research interest ahead of her presentation “Love thy neighbor – unraveling the tumor-immune microenvironment using multiplexed imaging” at the upcoming Multiplex technologies to advance immuno-oncology and oncology discoveries session, on February 23.
Abcam is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. P.A.C.E credits are available for the live sessions and can be requested after each session.
All Abcam’s PACE-certified webinars are free and available on-demand.
Immuno-oncology research solutions
Discover solutions to support your cancer immunotherapy response and resistance research
Registered Office:
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
VIEW PRODUCTS
© Abcam Limited. all rights reserved.
Abcam Limited is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds.
